Nutrition supplementation and immunity in athletes
Effects of butyrylated high amylose maize starch compared to low amylose maize starch on faecal microbiology and immunity in athletes.
Australian Institute of Sport
40 participants
Oct 20, 2008
Interventional
Conditions
Summary
This study will investigate 28 days of butyrylated resistant starch supplementation on faecal short chain fatty acids, faecal microbiology and immunity in well trained athletes. Well trained athletes undertaking prolonged endurance exercise suffer gastrointestinal dysfunction and suppression of immunity from heavy exercise training. This supplement is being investigated to examine whether it may reverse these issues.
Eligibility
Inclusion Criteria1
- Normal biochemistry and haematology, athletic training background of 3 years, a minimal maximal oxygen uptake (VO2max) of 45 ml/kg/min for women and 50 ml/kg/min for men, no use of immunomodulatory medicines.
Exclusion Criteria1
- No history of irritable bowel syndrome/disease, crohn's disease, autoimmune conditions.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
To examine the effect of butyrylated high amylose maize starch on immune and microbiological parameters in 40 well trained athletes in a double blind placebo controlled parallel trial over 28 days. Butyrylated high amylose maize starch is non-digestible starch that promotes the growth of beneficial microbes in the gastrointestinal tract. In this case the starch has had butyric acid incorporated into its structure. Butyric acid is the primary fuel for colonocytes and promotes normal functioning of these cells. The supplement is in a powder form and will be mixed and consumed with a protein drink (musashi protein powder) twice daily for 28 days. A total of 40 grams per day of the butyrylated high amylose maize starch will be consumed per day. The expected outcomes are an increase in faecal short chain fatty acids (butyrate, acetate and propionate), an increase in total faecal bacteria and increases in salivary antimicrobial proteins and serum cytokines.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000771954